[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590658":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":26,"collaborators":7,"id":28,"slug":7,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":33,"eligibilityCriteria":34,"healthyVolunteers":29,"sex":35,"minAge":36,"maxAge":7,"enrollmentInfo":37,"targetDuration":7,"studyType":40,"phases":7,"briefSummary":41,"conditions":42,"keywords":47,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"XEOS Medical","INDUSTRY",null,[9],{"facility":10,"status":11,"city":12,"state":7,"zip":7,"country":13,"cosmosGeoPoint":14,"geoPoint":19,"contacts":20},"AZ Maria Middelares","RECRUITING","Ghent","Belgium",{"type":15,"coordinates":16},"Point",[17,18],3.71667,51.05,{"lat":18,"lon":17},[21],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},"Dr. Ameye","CONTACT","+32 9 246 18 52","klinische.studies@mijnziekenhuis.be",{"type":27,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100590658",false,"NCT06970275","To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.","A Multicentric, Observational, Post-marketing, Registry Study to Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.","PETRiS","Inclusion Criteria :\n\nAll patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT.\n\nPatients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent.\n\nExclusion Criteria:\n\n* Under the age of 18 years at the time of resective surgery.\n* Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":38,"type":39},850,"ESTIMATED","OBSERVATIONAL","This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings. Additionally, it assesses how these imaging insights influence clinical decision-making and long-term patient outcomes. Through this comprehensive analysis in a real-world setting, the study seeks to generate valuable insights that can enhance specimen evaluation processes and ultimately improve patient care.",[43,44,45,46],"Prostate Cancers","Breast Cancer","Head and Neck Cancer","Cancer",[48,49,50,51],"PET-CT","Registry","Imaging","cancer","2026-06-22",{"date":54,"type":55},"2026-06-25","ACTUAL",{"date":57,"type":55},"2025-11-19",{"date":59,"type":39},"2031-01-15",{"name":5,"class":6},1]